Chemomab Therapeutics (CMMB) Receivables - Other (2017 - 2022)

Chemomab Therapeutics' (CMMB) quarterly Receivables - Other came in at $7000.0 in Q2 2022, down 66.67% on a QoQ basis from $21000.0 in Q4 2018.

Chemomab Therapeutics (CMMB) Receivables - Other (2017 - 2022) Analysis & Trends

Chemomab Therapeutics (CMMB) has 3 years of Receivables - Other data on file, last reported at $7000.0 in Q2 2022.

Quarterly Receivables - Other changed N/A year-over-year to $7000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $7000.0 (changed N/A YoY) and the FY2018 annual result came in at $21000.0, up 40.0% from the prior year.
Receivables - Other fell to $7000.0 in Q2 2022, from $21000.0 in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $21000.0 in Q4 2018 to a low of $7000.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.04 Bn	130.19 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.58 Bn	77.59 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.34 Bn	1.37 Bn
4	Moderna	56.52 Bn	51.38 Bn	52.00 Mn
5	BeOne Medicines	42.04 Bn	36.94 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.67 Bn	27.36 Bn	992.69 Mn
7	Insmed	27.27 Bn	26.11 Bn	358.27 Mn
8	BioNTech SE	27.14 Bn	8.75 Bn	668.28 Mn
9	Royalty Pharma	27.12 Bn	26.28 Bn	-
10	Chemomab Therapeutics	13.97 Mn	3.60 Mn	-

Download Data